Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Belite Bio, Inc
Belite Bio, Inc News
Belite Bio, Inc Quantitative Score
About Belite Bio, Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Belite Bio, Inc Earnings & Revenue
Belite Bio, Inc Financials
Table Compare
Compare BLTE metrics with: | |||
|---|---|---|---|
Earnings & Growth | BLTE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BLTE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BLTE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BLTE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Belite Bio, Inc Income
Belite Bio, Inc Balance Sheet
Belite Bio, Inc Cash Flow
Belite Bio, Inc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Belite Bio, Inc Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Belite Bio, Inc Executives
| Name | Role |
|---|---|
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | Chief Financial Officer & Director |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer |
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & Chief Executive Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer | 1969 | -- | |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | Chief Financial Officer & Director | Male | 1984 | -- |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer | 1967 | -- | |
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & Chief Executive Officer | 1978 | -- |